Also, the precedentialclaims regarding the remarkable antitumor potential of dual LSD1–HDACinhibitors in diverse malignancies strengthened our envisionment ofextracting amplified anti-CRC effects via simultaneous inhibitionof LSD1 and HDAC. Here, HDAC9 is linked to colorectal carcinoma.